# Testagen — Research Peptide Profile

> Testagen (KEDG, Lys-Glu-Asp-Gly) is a Khavinson-class bioregulator with bird-model thyroid data, no human trials, and unverified testosterone marketing claims.

Source: https://peptpedia.org/peptide/testagen | Published: 2026-09-18 | Last updated: 2026-09-18

Testagen is the trade name for KEDG (Lys-Glu-Asp-Gly), a synthetic tetrapeptide modeled on anterior pituitary peptide composition. Its only indexed experimental evidence comes from hypophysectomized bird studies showing partial restoration of thyroid axis hormones. Claims of testicular or testosterone effects have no published experimental support.

## Overview

Testagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Gly (KEDG), synthesized on the basis of the amino acid composition of peptide complexes from the anterior pituitary gland. It belongs to the Khavinson-school class of short peptide bioregulators and is marketed in Russia as a dietary supplement rather than a registered drug. The indexed literature consists of a small series of studies by the Kuznik group at Chita State Medical Academy in hypophysectomized chickens and hens, in which KEDG administration for 40 days partially restored thyrotropin and thyroid hormone concentrations, thyroid gland morphology, thymic structure, and selected immune and hemostatic parameters. In those experiments KEDG was compared with Ala-Glu-Asp-Gly, the pineal tetrapeptide better known as [Epithalon](/peptide/epithalon). Vendor materials frequently describe Testagen as a testicular bioregulator, but no PubMed-indexed study has examined KEDG in testicular tissue or measured testosterone outcomes. No human trial, pharmacokinetic study, or independent replication outside Russian research groups has been published.

## Molecular Profile

- **Category:** bioregulators
- **Molecular formula:** C17H29N5O9
- **Molecular weight:** 447.44 g/mol
- **Amino acid sequence:** Lys-Glu-Asp-Gly
- **Also known as:** KEDG, Lys-Glu-Asp-Gly
- **Half-life:** Not established; no pharmacokinetic study has been published
- **Solubility:** Soluble in water
- **Storage:** Store lyophilized at -20°C.

## Mechanism of Action

The bioregulator framework proposes that ultrashort peptides penetrate cells and interact directly with DNA promoter regions to modulate gene expression in a tissue-selective manner. A 2023 molecular docking study from that research network found KEDG among the most effective computed ligands of the LAT1, LAT2, and PEPT1 amino acid and peptide transporters, suggesting a possible route of cellular uptake. In hypophysectomized birds, KEDG administration was associated with recovery of pituitary-thyroid axis output, which the authors interpreted as compensatory regulation of thyrotropin release. No receptor target has been identified at molecular resolution, and no mechanism has been demonstrated in mammals.

## Key Research Findings

- Testagen (KEDG, Lys-Glu-Asp-Gly) is modeled on anterior pituitary peptide composition; every indexed experimental study of it was performed in hypophysectomized birds, not mammals or humans.
- Forty-day KEDG administration in hypophysectomized chickens and hens partially restored thyrotropin, thyroid hormones, thyroid morphology, and thymic structure, with weaker effects in old hens.
- Vendor claims that Testagen supports testes or testosterone have no PubMed-indexed experimental support; no study has measured testosterone outcomes with KEDG.
- A 2023 docking study proposed LAT1, LAT2, and PEPT1 transporters as a cellular uptake route for KEDG, the only molecular-level evidence in its literature.

## Testagen Pharmacokinetics: No Measured Parameters in Any Species

No pharmacokinetic study - no plasma half-life, bioavailability, distribution, or clearance measurement - has been published for KEDG (Testagen) in any species. As an unmodified tetrapeptide it is expected to degrade rapidly in plasma, but that expectation is extrapolation from peptide class behavior rather than measurement.

### Class-Level Expectations Only

- Unmodified tetrapeptides are typically cleared within minutes by plasma and tissue peptidases; no KEDG-specific measurement exists to confirm or modify that expectation.
- A 2023 molecular modeling study reported KEDG as a high-affinity computed ligand of LAT1, LAT2, and PEPT1 transporters, which the authors propose as a cellular uptake route; this is in silico evidence only and does not establish exposure in vivo (PMID 36979488).

### What the Animal Protocols Imply

- In the hypophysectomized bird studies, KEDG was administered over 40-day courses with hormonal and histological endpoints; no blood concentrations of the peptide were measured (PMID 19024016).
- Effects persisting across a 40-day course were attributed by the authors to gene-level regulation rather than continuous receptor occupancy, consistent with the transient-trigger model used across the Khavinson bioregulator literature.

## Safety & Tolerability

There are no human safety data for Testagen: no clinical trial, no pharmacokinetic study, and no formal toxicology assessment exist in indexed literature. The only in vivo evidence is 40-day administration in hypophysectomized birds, which reported no toxicity but used no formal safety endpoints. Widely repeated marketing claims of testicular or testosterone effects have no indexed experimental support.

**Human data status:** No human data of any kind: no interventional, observational, or pharmacokinetic study of KEDG in humans has been published.

**Regulatory status:** Not approved as a drug by the FDA, EMA, or any major regulator; sold in Russia as a biologically active food supplement (BAFS) and elsewhere as a research chemical.

- In hypophysectomized bird studies, KEDG was administered for 40 days with restoration of thyroid-axis endpoints and no reported toxicity, but the studies included no formal safety evaluation and were not designed to detect adverse effects. (evidence tier: animal; [PMID 19024016](https://pubmed.ncbi.nlm.nih.gov/19024016/))
- The only molecular-level evidence for KEDG is a 2023 computational docking study proposing LAT and PEPT transporter uptake; in silico affinity does not establish exposure, distribution, or tolerability in any species. (evidence tier: theoretical; [PMID 36979488](https://pubmed.ncbi.nlm.nih.gov/36979488/))

## Dosing Information (Research Context)

No human dosing has been established. Published experiments administered Lys-Glu-Asp-Gly to hypophysectomized birds over 40-day courses. The only other indexed research context is a 2023 molecular docking study. Any human-oriented dosing schedules circulating online derive from vendor marketing, not published trials.

## Researched Effects

- **Thyroid Axis Restoration (Avian Models)** (evidence: moderate): Across several controlled experiments in hypophysectomized chickens and old hens, KEDG administration for 40 days increased circulating thyrotropin and thyroid hormone concentrations and improved thyroid gland morphology toward normal structure. The effect was significant in young birds and less pronounced in old hens, an age dependence the authors reported explicitly. These findings come from a single research group (Kuznik et al., Chita State Medical Academy), have not been independently replicated, and the avian hypophysectomy model does not map directly onto human thyroid dysfunction.
- **Thymic Structure Support** (evidence: preliminary): In hypophysectomized young and old birds, KEDG promoted recovery of thymic morphology, with a more pronounced effect than the comparison peptide Ala-Glu-Asp-Gly. The authors interpret this as evidence of anterior pituitary peptide influence on immune organ structure, a single-group finding in an avian model without mammalian confirmation.
- **Immune and Hemostasis Parameter Normalization** (evidence: preliminary): A Russian-language study in neonatally hypophysectomized chickens and one-year-old birds reported that KEDG prevented atrophic thyroid changes while normalizing immune and hemostatic parameters, in a model that produced depressed immunity, hypercoagulation, and depressed fibrinolysis. English-language detail on assays and effect sizes is limited to the abstract.
- **Cellular Uptake via LAT and PEPT Transporters (Computational)** (evidence: preliminary): A 2023 docking analysis of 26 ultrashort peptides found KEDG among the most effective computed ligands of the LAT1, LAT2, and PEPT1 transporters and proposed that such transport may underlie the biological activity of short peptides. This is computational chemistry, not a cellular or animal transport experiment.

## Research Applications

- Endocrine Research
- Peptide Bioregulation
- Avian Hypophysectomy Models
- Aging Research

## Key Studies

### Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens

Kuznik BI, Pateyuk AV, Rusaeva NS — *Bulletin of Experimental Biology and Medicine* (2008) — [PMID 19024016](https://pubmed.ncbi.nlm.nih.gov/19024016/) | [doi:10.1007/s10517-008-0033-6](https://doi.org/10.1007/s10517-008-0033-6)

This study introduced the synthetic tetrapeptides Lys-Glu-Asp-Gly (KEDG) and Ala-Glu-Asp-Gly, designed from the amino acid composition of pituitary cytomedins, in neonatally hypophysectomized chickens. Administration for 40 days increased concentrations of thyrotropic hormone and thyroid hormones and was accompanied by recovery of thyroid gland structure. It is the foundational experimental paper for the peptide later marketed as Testagen, and it establishes that the indexed evidence base for KEDG is avian and pituitary-thyroid in orientation, not testicular.

### Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens

Kuznik BI, Pateyuk AV, Rusaeva NS, Baranchugova LM, Obydenko VI — *Bulletin of Experimental Biology and Medicine* (2011) — [PMID 22268052](https://pubmed.ncbi.nlm.nih.gov/22268052/) | [doi:10.1007/s10517-011-1177-3](https://doi.org/10.1007/s10517-011-1177-3)

This follow-up compared KEDG (the anterior pituitary peptide) and Ala-Glu-Asp-Gly (the posterior pituitary peptide) in hypophysectomized young chickens and old hens. Both peptides significantly reduced hormonal disturbances and structural thyroid changes over 40 days, with the normalizing effect on thyrotropic hormone and thyroid hormones less pronounced in old hens than in young birds, an explicit age-dependence finding.

### Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds

Pateyk AV, Baranchugova LM, Rusaeva NS, Obydenko VI, Kuznik BI — *Bulletin of Experimental Biology and Medicine* (2013) — [PMID 23658898](https://pubmed.ncbi.nlm.nih.gov/23658898/) | [doi:10.1007/s10517-013-2029-0](https://doi.org/10.1007/s10517-013-2029-0)

This study examined thymus morphology in hypophysectomized young and old birds. Neonatal hypophysectomy produced the most pronounced thymic changes, and administration of KEDG or Ala-Glu-Asp-Gly promoted recovery of thymic structures regardless of age; the anterior pituitary peptide KEDG showed the stronger effect on thymic recovery.

### Effects of hypophyseal Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly synthetic peptides on immunity, hemostasis, morphology and functions of the thyroid gland in neonatally hypophysectomized chicken and one-year-old birds

Kuznik BI, Pateiuk AV, Rusaeva NS, Baranchugova LM, Obydenko VI — *Patologicheskaia Fiziologiia i Eksperimental'naia Terapiia* (2010) — [PMID 20731122](https://pubmed.ncbi.nlm.nih.gov/20731122/)

This Russian-language study profiled immunity, hemostasis, and thyroid morphology and function in neonatally hypophysectomized chickens and one-year-old birds. Hypophysectomy produced enlarged thyroid follicles, depressed immunity, hypercoagulation, and depressed fibrinolysis; KEDG and Ala-Glu-Asp-Gly administration prevented atrophic thyroid changes and normalized immune and hemostatic parameters. Only the abstract is available in English, so assay-level detail is limited.

### Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters

Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG — *Biomolecules* (2023) — [PMID 36979488](https://pubmed.ncbi.nlm.nih.gov/36979488/) | [doi:10.3390/biom13030552](https://doi.org/10.3390/biom13030552)

This molecular modeling and docking study assessed whether 26 biologically active ultrashort peptides can be transported into cells via LAT and PEPT family transporters. KEDG was among the most effective computed ligands of LAT1, LAT2, and PEPT1, outperforming most of the 8400 possible di- and tripeptides analyzed. The authors propose transporter-mediated uptake as a general mechanism of ultrashort peptide activity; the work is computational and does not measure transport in cells or animals.

## Frequently Asked Questions

### What is Testagen?

Testagen is the trade name for the synthetic tetrapeptide KEDG (Lys-Glu-Asp-Gly), designed from the amino acid composition of anterior pituitary peptide complexes. It belongs to the Khavinson school of short peptide bioregulators and is sold in Russia as a dietary supplement. Its indexed research base consists of hypophysectomized bird studies and one molecular docking analysis; no human studies exist.

### Is Testagen a testosterone booster?

No published evidence supports that claim. Vendor marketing often describes Testagen as a testicular or testosterone-supporting bioregulator, but the indexed literature on KEDG covers thyroid, thymus, immune, and coagulation endpoints in hypophysectomized birds. No PubMed-indexed study has tested KEDG in testicular tissue or measured testosterone. The marketing claim appears to extrapolate from the general observation that hypothyroidism is associated with reduced testosterone, which is not evidence that KEDG raises testosterone.

### What research has been done on Testagen?

Four indexed experimental papers, all from the Kuznik group at Chita State Medical Academy, studied KEDG in hypophysectomized chickens and hens: 40-day administration partially restored thyrotropin and thyroid hormone levels, thyroid morphology, thymic structure, and immune and hemostatic parameters. A 2023 molecular modeling paper from the Khavinson group proposed LAT1, LAT2, and PEPT1 transporter uptake. No mammalian efficacy study, human trial, or pharmacokinetic study has been published.

### Is Testagen safe?

Human safety is uncharacterized: there are no human trials, no pharmacokinetic data, and no formal toxicology in indexed literature. The bird studies did not report toxicity during 40-day administration, but avian tolerance does not predict human safety. Products sold online as Testagen are research chemicals or Russian dietary supplements without pharmaceutical-grade oversight.

## Related Peptides

- [Epithalon](https://peptpedia.org/peptide/epithalon)
- [Vilon](https://peptpedia.org/peptide/vilon)
- [Vesugen](https://peptpedia.org/peptide/vesugen)
- [Thymalin](https://peptpedia.org/peptide/thymalin)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org